PCRX vs CRON

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 23, 2026

PCRX

58.6
AI Score
VS
PCRX Wins

CRON

33.3
AI Score

Investment Advisor Scores

PCRX

59score
Recommendation
HOLD

CRON

33score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PCRX CRON Winner
Revenue 369.77M 98.22M PCRX
Net Income 7.57M 45.84M CRON
Net Margin 2.0% 46.7% CRON
Operating Income 11.17M 5.57M PCRX
ROE 1.1% 4.3% CRON
ROA 0.6% 3.9% CRON
Total Assets 1.24B 1.18B PCRX
Cash 205.88M 467.02M CRON
Current Ratio 5.04 16.18 CRON
Free Cash Flow 79.08M 31.29M PCRX

Relative Price Performance (Last 90 Days)

PCRX 1M: -4.9% · 3M: +5.1% CRON 1M: +20.8% · 3M: +21.2%

Current Technical Phase

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.5 · Price: $24.67

CRON

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.3% over 20 days), RSI 69

RSI (14): 69.3 · Price: $3.31

Fundamentals Snapshot

Metric PCRX CRON
Market Cap
Forward P/E 6.9 20.9
Trailing P/E 67.7 16.9
Revenue (TTM)
Revenue Growth 0.1% 0.6%
Gross Margin 0.8% 0.4%
Operating Margin 0.1% 0.2%
EPS 0.36 0.19
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.